Humacyte Stock Today

HUMAW Stock  USD 0.89  0.01  1.14%   

Performance

Very Weak

 
Weak
 
Strong

Odds Of Distress

Very High

 
High
 
Low
Humacyte is selling for under 0.89 as of the 16th of March 2025; that is 1.14 percent increase since the beginning of the trading day. The stock's lowest day price was 0.77. Humacyte has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
24th of November 2020
Category
Healthcare
Classification
Health Care
Humacyte is entity of United States. It is traded as Stock on NASDAQ exchange. More on Humacyte

Moving together with Humacyte Stock

  0.72ENVB Enveric Biosciences Earnings Call Next WeekPairCorr

Moving against Humacyte Stock

  0.83IVA Inventiva SaPairCorr
  0.68LLY Eli LillyPairCorr
  0.68PBH Prestige Brand HoldingsPairCorr
  0.59KRYS Krystal BiotechPairCorr
  0.58VIGL Vigil NeurosciencePairCorr
  0.56MGTX MeiraGTx Holdings PLC Downward RallyPairCorr

Humacyte Stock Highlights

Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.01730.0088
Way Up
Slightly volatile
Total Current Liabilities15.7 M21.2 M
Way Down
Slightly volatile
Non Current Liabilities Total126.2 M86.6 M
Way Up
Slightly volatile
Total Assets196.8 M147.5 M
Significantly Up
Very volatile
Total Current Assets132.7 M95.8 M
Significantly Up
Slightly volatile
Humacyte can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Humacyte's financial leverage. It provides some insight into what part of Humacyte's total assets is financed by creditors.
Liquidity
Humacyte has accumulated 57.51 M in total debt. Note, when we think about Humacyte's use of debt, we should always consider it together with its cash and equity.

Capital Expenditures

1.92 Million
Humacyte (HUMAW) is traded on NASDAQ Exchange in USA. It is located in 2525 East North Carolina Highway 54, Durham, NC, United States, 27713 and employs 183 people. Humacyte is listed under Biotechnology category by Fama And French industry classification. The company classifies itself under Biotechnology sector and is part of Health Care industry. Humacyte generates negative cash flow from operations
Check Humacyte Probability Of Bankruptcy

Humacyte Historical Income Statement

At this time, Humacyte's Cost Of Revenue is fairly stable compared to the past year. Interest Income is likely to climb to about 6.9 M in 2025, whereas Interest Expense is likely to drop slightly above 1.2 M in 2025. View More Fundamentals

Humacyte Stock Against Markets

Humacyte Corporate Management

Harold AltersonSenior QualityProfile
MS MSChief OfficerProfile
Sabrina OsborneExecutive PeopleProfile
Kiernan MDChief OfficerProfile
Dale SanderChief CFOProfile
William ScheesseleChief OfficerProfile

Additional Tools for Humacyte Stock Analysis

When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.